Axicabtagene Ciloleucel
Refractory High Grade B-Cell Lymphoma
AIDS Malignancy ConsortiumCell therapyPhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Refractory High Grade B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Evorpacept M.D. Anderson Cancer Center | Phase 1/2 | CCC |
Efineptakin Alfa NeoImmuneTech | Phase 1 | CC |
Same molecule, other indications
Axicabtagene Ciloleucel is also rated in:
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell LymphomaDormant
BBB
Indicative ·
77 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →